Literature DB >> 19052742

Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.

Ilyssa O Gordon, Takisha Wade, Kevin Chin, Jerome Dickstein, Thomas F Gajewski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19052742     DOI： 10.1007/s00262-008-0627-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


× No keyword cloud information.
  27 in total

Review 1.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

Review 2.  Immunomodulatory therapy for melanoma: ipilimumab and beyond.

Authors:  Margaret K Callahan; Michael A Postow; Jedd D Wolchok
Journal:  Clin Dermatol       Date:  2013 Mar-Apr       Impact factor: 3.541

3.  Challenges in the use of immunotherapy in metastatic melanoma.

Authors:  Ashley Tran; Shayna Sarosiek; Naomi Y Ko
Journal:  BMJ Case Rep       Date:  2016-11-18

Review 4.  The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics.

Authors:  Jessica Menis; Saskia Litière; Konstantinos Tryfonidis; Vassilis Golfinopoulos
Journal:  Ann Transl Med       Date:  2016-07

Review 5.  Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.

Authors:  Lisa A Kottschade
Journal:  Curr Oncol Rep       Date:  2018-03-06       Impact factor: 5.075

6.  Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells.

Authors:  Birgit Tsaknakis; Inga-Marie Schaefer; Harald Schwörer; Carsten-Oliver Sahlmann; Kai-Martin Thoms; Martina Blaschke; Giuliano Ramadori; Silke Cameron
Journal:  Med Oncol       Date:  2013-12-14       Impact factor: 3.064

Review 7.  Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.

Authors:  Shannon K Quirk; Anna K Shure; Devendra K Agrawal
Journal:  Transl Res       Date:  2015-06-11       Impact factor: 7.012

Review 8.  Immune Checkpoint Blockade in Cancer Therapy.

Authors:  Michael A Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

Review 9.  Ipilimumab and its toxicities: a multidisciplinary approach.

Authors:  Leslie A Fecher; Sanjiv S Agarwala; F Stephen Hodi; Jeffrey S Weber
Journal:  Oncologist       Date:  2013-06-17

Review 10.  Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes.

Authors:  Troy Dillard; Chris G Yedinak; Joshi Alumkal; Maria Fleseriu
Journal:  Pituitary       Date:  2009-07-29       Impact factor: 4.107
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.